linjc16/ctgov huggingface dataset:
Oxytocin and Resting State fMRI

Study Overview
=================
Brief Summary
-----------------
The goal of the study is to investigate the effects of intranasal oxytocin (OT) or placebo to resting state brain activity in healthy males.

Detailed Description
-----------------
Although several fMRI studies investigated the neural correlates of OT administration, only few have focused on the underlying modulatory effects of OT on baseline brain function. While functional MRI examines the neural activity during a certain task, it might be especially interesting to assess the main effect of OT on the basic activity of the human brain in rest. This resting state activity becomes typically evident in the default mode network (DMN), compromising midline structures such as medial frontal cortex, cingulate and precuneus, as well as specific resting state networks . In fact, a recent study succeeded in demonstrating a modulatory influence of OT. Recent studies were able to show an increased functional connectivity at rest of amygdala to the medial prefrontal cortex (PFC) in a small sample of 15 subjects. However, distinct subregions of the amygdala seem to be involved in different OT effects. To goal of the present study is to decipher the modulatory effects of OT to subregions of the amygdala in a larger sample using improved anatomical mapping of the seed regions and relate these alterations to individual traits of healthy volunteers. We expected to add evidence to the increase of amygdala - PFC connectivity under OT as well as detailed anatomical mapping of this networks.

Official Title
-----------------
Intranasal Oxytocin and Resting State fMRI in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Oxytocin
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health Exclusion Criteria: Chronic physical or mental illness, regular smoking or alcohol consumption and medication intake

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: OT<br>Oxytocin | Drug: Oxytocin<br> <br> |
| Placebo Comparator: Placebo<br>Placebo | Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resting state brain activity using fMRI |  | 30min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subject personality using questionnaires |  | 30min |
A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema

Study Overview
=================
Brief Summary
-----------------
This study will assess the impact of lymphaticovenous microanastomosis in volume reduction of postmastectomy upper extremity lymphedema. We hypothesize that multiple lymphaticovenous micro-anastomosis in the distal arm will result in the reduction of volume and improvement in quality of life of patients with post-mastectomy lymphedema

Official Title
-----------------
A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema

Conditions
-----------------
Lymphedema, Post Mastectomy

Intervention / Treatment
-----------------
* Procedure: Lymphaticovenous Micro-Anastomosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is 18-70 years of age Subject is Stage II-IV unilateral lymphedema Exclusion Criteria: Subject is less than 6 months from completion of cancer treatment Subject has allergic reaction to the lymphatic contrast agent (Indocyanine Blue) Subject is medically unfit for the procedure Subject is unable to complete the follow-up visits Women with a positive urine pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence. Subject has bilateral lymphedema

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: A lymphatic diversion with lymphaticovenous microanastomosis will be performed.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lymphaticovenous Micro-Anastomosis<br> | Procedure: Lymphaticovenous Micro-Anastomosis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes Relative to Baseline in the Volume of the Affected Limb at 3 and 6 Months From Surgery | Lymphatic Volumetric Assessment. Evaluation of the volumetric change, relative to baseline measurement, in the volume of the affected limb at 3 and 6 months from the procedure. | 3 and 6 months from surgery |
Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the stability of capillary HBA1c blood samples collected by the participant with this kit and mailed to the laboratory at Children's Mercy Hospital.

Detailed Description
-----------------
Participants are given home lab kit for obtaining HbA1c by capillary blood and shipping it to Children's Mercy Hospital and Clinics. They will mail in sample before their next visit and this result will be compared to the HbA1c performed during this visit.

Official Title
-----------------
Assessment of Stability and Ease of Use of a Mail-in Capillary Blood Hemoglobin A!c Sample Kit

Conditions
-----------------
Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female diabetic patients ages 1-17 years who have an A1c test drawn within 24 hours Participants receiving medical care in the Endocrine Clinic at Children's Mercy Hospital Exclusion Criteria: Not meeting above inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes
A New Parameter Derived From DSA to Evaluate Cerebral Perfusion

Study Overview
=================
Brief Summary
-----------------
This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.

Detailed Description
-----------------
Ischemic cerebrovascular disease is an important cause of death and disability in the world. Digital Subtraction Angiography (DSA) is the golden index for evaluating cerebral blood vessels. We introduced a new parameter derived from DSA to evaluate the perfusion to predict the outcomes in acute stroke with large vessel occlusion. To study the possible relationship between the new parameter of cerebral perfusion derived from DSA and outcomes in cerebral ischemia（modified Rankin Scale）, we intend to retrospectively analyze the images derived from patients who undergone the DSA and follow-up outcomes（modified Rankin Scale）.

Official Title
-----------------
The Association Between a New Parameter Derived From DSA and Outcomes in Cerebral Ischemia

Conditions
-----------------
Cerebral Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebral ischemia patients undergone DSA Exclusion Criteria: 1.cerebral hemorrhage
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| good perfusion in DSA<br>We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(good perfusion) | |
| middle perfusion in DSA<br>We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(middle perfusion) | |
| poor perfusion in DSA<br>We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(poor perfusion) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the outcomes between good perfusions and poor perfusions | Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). | 3 months to 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the outcomes between good perfusions and middle perfusions | Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). | 3 months to 2 years |
Children's Deep Neck Infections at the Montpellier Hospital

Study Overview
=================
Brief Summary
-----------------
To descride the clinical presentation, diagnosis, management and complications of children with a deep neck infection. A retrospective chart review was conducted at the Montpellier hospital in France. All children aged less than 18 years who had been admitted with a diagnosis of cervical phlegmon, tonsillar abscesses, retropharyngeal or parapharyngeal abscesses between January 2015 and December 2017 were included. The investigators collected the demographic, biological, radiological data and treatment received of the patients to the admision. The results of the bacteriological samples were collected. The investigators compared our results to those of the 10-year cohort. The investigators wish to compare the duration of hospitalization and the duration of the fever enter the group treated by alone antibiotic and the group treated by antibiotic and surgical drainage

Official Title
-----------------
Retrospective Evaluation of the Management of Children's Deep Neck Infections at the Montpellier Hospital

Conditions
-----------------
Deep Neck Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: under 18 years old hospitalized for acute pharyngeal infection ( cervical phlegmon, tonsillar abscesses, retropharyngeal or parapharyngeal abscesses) Exclusion criteria: neck infection in the context of immune deficiency malignancy or post-traumatic disease others deep neck infections: angina, otitis, sinusitis, ethmoiditis, mastoiditis.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical description of acute peripharyngeal suppuration | Clinical description of acute peripharyngeal suppuration suppuration | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of therapeutic management | Description of therapeutic management : vaccinations, treatments received before hospitalization, treatments received during hospitalization | 1 day | 
| Description of bacteria in deep neck infections | Description of bacteria in deep neck infections | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervical phlegmon, tonsillar abscesses, retropharyngeal or parapharyngeal abscesses, medical and chirurgical treatment, Bacteria in deep neck infections
Reduction or Extension of COnduction Time With Ventricular Electromechanical Remodeling (RECOVER)

Study Overview
=================
Brief Summary
-----------------
This prospective multicenter registry study aims to detect the serial changes in ventriculo-ventricular conduction times according to cardiac-resynchronization therapy response.

Official Title
-----------------
Prospective Multicenter Observation Study on the Serial Changes in Ventriculo-ventricular Conduction Times According to Cardiac-resynchronization Therapy Response

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Diagnostic Test: Device interrogation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: meeting the current ESC or ACCF/AHA/HRS Class I or Class IIa indications for cardiac-resynchronization (CRT) implant Exclusion Criteria: Myocardial infarction, unstable angina within 40 days prior the enrollment Recent cardiac revascularization in the 4 weeks prior to the enrollment or planned for the 3 months following Cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months prior to the enrollment Primary valvular disease requiring surgical correction Pregnant or are planning during the duration of the investigation Status 1 candidate for cardiac transplantation or consideration for transplantation over the next 12 months Post-cardiac transplantation Life expectancy < 12 months Currently participating in any other clinical investigation except for observational registry

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CRT responder<br> | Diagnostic Test: Device interrogation<br>* Ventriculo-ventricular conduction time measurement using device analyzer<br>|
| CRT non-responder<br> | Diagnostic Test: Device interrogation<br>* Ventriculo-ventricular conduction time measurement using device analyzer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serial change of ventriculo-ventricular conduction times | Reduction or extension of ventriculo-ventricular conduction times | from enrollment to last follow-up (2 years) |
Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity

Study Overview
=================
Brief Summary
-----------------
The very low carbohydrates diet (VLCKD) induces liver steatosis amelioration. Lysosomal acid lipase (LAL) deficiency plays a role in fats accumulation in liver. To date, no studies have assessed LAL activity in morbid obesity. The aim of our study is to evaluate VLCKD impact on metabolic/vascular parameters and LAL activity in obese patients. A VLCKD is administered for 25 days to 52 morbid obese patients (BMI 44.7±8.3 kg/m², age 49±12.5 years); at baseline and after diet we evaluated: BMI, glyco-lipidic pattern, abdominal ultrasonography (liver steatosis and visceral fat area) and flow-mediated dilation (FMD). In a subgroup of 20 patients we also tested lysosomal acid lipase (LAL)-activity. A group of healthy normal weight subjects (age 43±13, BMI 22.8±2.6 kg/m²) was also included in the study.

Official Title
-----------------
Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity

Conditions
-----------------
Lysosomal Acid Lipase Deficiency, Obesity, Ketogenic Dieting, Ketosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI > 40 Kg/m2 or > 35 kg/m2 with comorbidities Exclusion Criteria: Type-2 diabetes Kidney, heart or liver failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| obese subjects<br> | |
| lean subjects<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lysosomal acid lipase activity | LAL-activity was dosed with dried blood spot (DBS) technique using the inhibitors Lalistat 2 | change from baseline after 25 days | 
| endothelial function | flow mediated dilation at brachial artery by ultrasonography | change from baseline after 25 days | 
| visceral fat | ultrasonography | change from baseline after 25 days | 
| liver steatosis | ultrasonography | change from baseline after 25 days | 
| lipid assessment | total cholesterol, triglycerides, HDL, LDL | change from baseline after 25 days | 
| general adiposity assessment | bioimpedentiometry | change from baseline after 25 days |
Binge Drinking And Addiction : Case-Control Study in Hospital

Study Overview
=================
Brief Summary
-----------------
Case Control Study : Objective: Frequent Binge drinking during 18-25 years is a risk factor of alcohol addiction in adulthood (25-40 years) Hypothesis: 25% of frequent binge drinking, OR = 2, power 80%, alpha risk : 5% 126 Cases aged 25 to 40 years: alcohol addict patients recruited in Addiction Unit in Rouen University Hospital 126 controls aged 25 to 40 years: non alcohol addict recruited by the Clinical investigation center in Rouen University Hospital An anonymous self-questionnaire was completed Binge Drinking during 18-25 years was retrospectively evaluated Confusion biais was also recorded

Official Title
-----------------
Binge Drinking And Addiction : Case-Control Study in Hospital

Conditions
-----------------
Alcohol Dependence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria 25 to 40 years: alcohol addiction for the cases Exclusion criteria age <20 and >40 alcohol addiction for the controls

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequent binge drinking |  | 18-25 years old | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
binge drinking
sgp130 in Chronic Human Liver Disease

Study Overview
=================
Brief Summary
-----------------
Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Detailed Description
-----------------
Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Official Title
-----------------
Study of IL-6 Transsignaling in Chronic Human Liver Disease

Conditions
-----------------
Alcoholic Liver Disease, Chronic Hepatitis C Virus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Alcohol excess intake and suspected liver disease Alcohol excess intake and clinical liver cirrhosis chronic hepatitis C virus infection and suspected liver disease chronic hepatitis C virus infection and clinical liver cirrhosis Exclusion Criteria: other (superimposed) liver disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| alcoholic liver disease<br>alcoholic liver disease patients undergoing a transjugular liver biospy in our institution | |
| chronic HCV hepatitis<br>chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver, alcohol, HCV